356 related articles for article (PubMed ID: 28419415)
1. Allostery at opioid receptors: modulation with small molecule ligands.
Livingston KE; Traynor JR
Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415
[TBL] [Abstract][Full Text] [Related]
2. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.
Burford NT; Traynor JR; Alt A
Br J Pharmacol; 2015 Jan; 172(2):277-86. PubMed ID: 24460691
[TBL] [Abstract][Full Text] [Related]
3. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
[TBL] [Abstract][Full Text] [Related]
4. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.
Burford NT; Clark MJ; Wehrman TS; Gerritz SW; Banks M; O'Connell J; Traynor JR; Alt A
Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10830-5. PubMed ID: 23754417
[TBL] [Abstract][Full Text] [Related]
5. Insights into the function of opioid receptors from molecular dynamics simulations of available crystal structures.
Marino KA; Shang Y; Filizola M
Br J Pharmacol; 2018 Jul; 175(14):2834-2845. PubMed ID: 28266020
[TBL] [Abstract][Full Text] [Related]
6. Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.
Wang J; Lindstrom J
Br J Pharmacol; 2018 Jun; 175(11):1805-1821. PubMed ID: 28199738
[TBL] [Abstract][Full Text] [Related]
7. Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects.
Kandasamy R; Hillhouse TM; Livingston KE; Kochan KE; Meurice C; Eans SO; Li MH; White AD; Roques BP; McLaughlin JP; Ingram SL; Burford NT; Alt A; Traynor JR
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846240
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.
Livingston KE; Traynor JR
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18369-74. PubMed ID: 25489080
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.
Dietis N; Niwa H; Tose R; McDonald J; Ruggieri V; Filaferro M; Vitale G; Micheli L; Ghelardini C; Salvadori S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Pharmacol; 2018 Jul; 175(14):2881-2896. PubMed ID: 29524334
[TBL] [Abstract][Full Text] [Related]
10. Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen.
Burford NT; Wehrman T; Bassoni D; O'Connell J; Banks M; Zhang L; Alt A
J Biomol Screen; 2014 Oct; 19(9):1255-65. PubMed ID: 25047277
[TBL] [Abstract][Full Text] [Related]
11. Emerging areas of opioid pharmacology.
Kelly E; Henderson G; Bailey CP
Br J Pharmacol; 2018 Jul; 175(14):2715-2716. PubMed ID: 29939423
[TBL] [Abstract][Full Text] [Related]
12. New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.
Vecchio EA; Baltos JA; Nguyen ATN; Christopoulos A; White PJ; May LT
Br J Pharmacol; 2018 Nov; 175(21):4036-4046. PubMed ID: 29679502
[TBL] [Abstract][Full Text] [Related]
13. Tuning Down the Pain - An Overview of Allosteric Modulation of Opioid Receptors: Mechanisms of Modulation, Allosteric Sites, Modulator Syntheses.
Bartuzi D; Wróbel TM; Kaczor AA; Matosiuk D
Curr Top Med Chem; 2020; 20(31):2852-2865. PubMed ID: 32479245
[TBL] [Abstract][Full Text] [Related]
14. Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors.
Shang Y; Yeatman HR; Provasi D; Alt A; Christopoulos A; Canals M; Filizola M
ACS Chem Biol; 2016 May; 11(5):1220-9. PubMed ID: 26841170
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors.
Livingston KE; Stanczyk MA; Burford NT; Alt A; Canals M; Traynor JR
Mol Pharmacol; 2018 Feb; 93(2):157-167. PubMed ID: 29233847
[TBL] [Abstract][Full Text] [Related]
16. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
Janero DR; Thakur GA
Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
[TBL] [Abstract][Full Text] [Related]
17. Strategies towards safer opioid analgesics-A review of old and upcoming targets.
Varga BR; Streicher JM; Majumdar S
Br J Pharmacol; 2023 Apr; 180(7):975-993. PubMed ID: 34826881
[TBL] [Abstract][Full Text] [Related]
18. Application of Mixed-Solvent Molecular Dynamics Simulations for Prediction of Allosteric Sites on G Protein-Coupled Receptors.
Chan WKB; Carlson HA; Traynor JR
Mol Pharmacol; 2023 May; 103(5):274-285. PubMed ID: 36868791
[TBL] [Abstract][Full Text] [Related]
19. Approaches for probing allosteric interactions at 7 transmembrane spanning receptors.
Klein MT; Vinson PN; Niswender CM
Prog Mol Biol Transl Sci; 2013; 115():1-59. PubMed ID: 23415091
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders.
Saito A; Alvi S; Valant C; Christopoulos A; Carbone SE; Poole DP
Br J Pharmacol; 2024 Jul; 181(14):2232-2246. PubMed ID: 36565295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
